touchONCOLOGY were delighted to talk to Prof. Ken Kato to discuss long-term safety and efficacy data from the ATTRACTION-1 study will support the potential role of nivolumab in esophageal squamous cell carcinoma.
The abstract ‘Nivolumab in advanced esophageal squamous cell carcinoma (ATTRACTION-1/ONO-4538-07): Minimum of five-year follow-up’ (Abstract number 207) was presented at ASCO’s virtual Gastrointestinal Cancers Symposium 2021,15-–17 January 2021.
Questions
- Could you tell us a little about the ATTRACTION-1 study and its findings? (0:30)
- What has the latest data shown us about the long-term efficacy and safety of nivolumab in advanced esophageal squamous cell carcinoma? (2:07)
- Could you give us a brief overview of the ATTRACTION clinical trial programme and other future and ongoing clinical studies in the trial? (4:20)
Disclosures: Prof. Ken Kato has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of ASCO’s Gastrointestinal Cancers Symposium 2021 (Virtual).
